Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis (Q37392767)

20 August 2017

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis (English)

1 reference

20 August 2017

0 references

0 references

8

Jacques Grosset

1 reference

20 August 2017

2

Eric Nuermberger

1 reference

20 August 2017

Deepak Almeida

1

1 reference

20 August 2017

Rokeya Tasneen

3

1 reference

20 August 2017

Ian Rosenthal

4

1 reference

20 August 2017

Sandeep Tyagi

5

1 reference

20 August 2017

Kathy Williams

6

1 reference

20 August 2017

Charles Peloquin

7

1 reference

20 August 2017

language of work or name

English

0 references

publication date

20 July 2009

1 reference

20 August 2017

7

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

20 August 2017

53

1 reference

20 August 2017

10

1 reference

20 August 2017

4178-4184

1 reference

Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

The chemical approach to the control of tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

The curious characteristics of pyrazinamide: a review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Present status of chemotherapy for tuberculosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Bioavailability of rifampin in experimental murine tuberculosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764177

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide

2 September 2018

1 reference

12 December 2020

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

1 reference

12 December 2020

Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong

1 reference

12 December 2020

Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.00830-09

1 reference

20 August 2017

1 reference

20 August 2017

1 reference